Alkermes still has room to grow
Despite trading near its 52-week high, the stock appears to have plenty left.
By Barry S. Cohen, Stock Traders Daily
Even though the company is pushing its 52-week high, the Dublin, Ireland company Alkermes (ALKS) may have quite a bit of upside for investors. The biopharmaceutical that once relied strictly on finding better ways to deliver existing drugs has some unique compounds in its pipeline that may not only help patients, but provide good value for payers.
The pipeline product the company is most enthusiastic about is an oral compound designed to compete with the best in class among oral antipsychotic agents. It's a combination of a proprietary new clinical entity of Alkermes and one of the most important antipsychotic drugs in the world called olanzapine, otherwise known as Zyprexa, a product of Eli Lilly (LLY).
This year the company plans to start testing the product in patients with schizophrenia, hoping that it is not only effective but doesn't have the undesirable side effects -- weight gain so sensitive that it can lead to diabetes -- of olanzapine. Our real time trading reports help investors identify companies like Alkermes that still have plenty of upside potential.
Of course, what's enabled the company to fund a beefed up research and development program is the success of its commercial offerings. The Alkermes line consists of about 25 products from which it earns royalties and/or manufacturing revenues. The mainstays of its line consist of what the company calls the big five. These products are unique in the classes in which they compete, are early in their patent life and will likely drive the revenue of Alkermes for the next ten years.
The latest addition to the big five is Bydureon, considered one of the most outstanding new biotechnology drugs to come along in the past several years. It's the first and only once weekly medication for Type II diabetic patients. Bydureon is a new class of molecule that was developed by developed by Alkermes' partners at Amylin. Last year, Bristol-Myers Squibb (BMY) bought Amylin for $7 billion, primarily to gets it hands on Bydureon.
To help finance the transaction, Bristol-Myers teamed up with AstraZeneca (AZN), which paid about half the purchase price and shares in the profits for Bydureon.
Alkermes earned royalty of $5.3 million on revenues of Bydureon during the company's fiscal third quarter ended December 31, 2012, pushing total revenue for the quarter up 8.2% from a year earlier and beating analyst estimates. In the reported quarter, Alkermes also scored a 10.3% gain to $52.5 million of manufacturing and royalty revenues from its long-acting atypical antipsychotic franchise comprising Risperdal Consta and Invega Sustenna/Xeplion. These drugs are marketed by Johnson & Johnson (JNJ).
Meanwhile, sales of its own product, Vivitrol, grew about 50% to nearly $15 million. Based on the excellent performance of Vivitrol, Alkermes raised its guidance for sales and earnings per share in fiscal 2013. For more information about stocks in this space, our real time trading reports help investors identify opportunities before they happen.
Copyright © 2014 Microsoft. All rights reserved.
Investors should note whether this phrase gets dropped from the Federal Reserve's policy statement after its September meeting.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.